#	Pagina
attuale pagina	/open-h2020/projects/212104/index.html
-1	/open-h2020/projects/208374/index.html

Opendata, web and dolomites

ImPRESS SIGNED

Imaging Perfusion Restrictions from Extracellular Solid Stress

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ImPRESS project word cloud

Explore the words cloud of the ImPRESS project. It provides you a very rough idea of what is the project "ImPRESS" about.

drugs medical direct questions effect drug impair conduct patients stress impress matrix series cancers observations unrivaled times scientific diagnostics successful repair time solid clinical critically q2 therapies coined vascular decompressing paradigm functional bed vivo reveal therapy perfect force perfusion treatment extracellular position biomarkers compressive human alleviating revitalize vasculature map engineering forces q1 radiation therapeutic rpi restricted dependent cancerous tumor humans restrictions innovative disease suggests first transferable caused promotes technologies anti imaging models pave conventional animal depleting vessels mechanical tumors holds resistance microenvironment image even chemo patient brain cancer answer q3

Project "ImPRESS" data sheet

The following table provides information about the project.

Coordinator	OSLO UNIVERSITETSSYKEHUS HF Organization address address: KIRKEVEIEN 166 TARNBYGGET city: OSLO postcode: 450 website: http://www.oslo-universitetssykehus.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Norway [NO]
Project website	https://www.ous-research.no/emblem/
Total cost	1˙499˙638 €
EC max contribution	1˙499˙638 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2017-STG
Funding Scheme	ERC-STG
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	OSLO UNIVERSITETSSYKEHUS HF OSLO UNIVERSITETSSYKEHUS HF Organization address address: KIRKEVEIEN 166 TARNBYGGET city: OSLO postcode: 450 website: http://www.oslo-universitetssykehus.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (OSLO)	coordinator	1˙499˙638.00

Map

Project objective

Even the perfect cancer drug must reach its target to have an effect. The ImPRESS project main objective is to develop a novel imaging paradigm coined Restricted Perfusion Imaging (RPI) to reveal - for the first time in humans - vascular restrictions in solid cancers caused by mechanical solid stress, and use RPI to demonstrate that alleviating this force will repair the cancerous microenvironment and improve therapeutic response. Delivery of anti-cancer drugs to the tumor is critically dependent on a functional vascular bed. Developing biomarkers that can measure how mechanical forces in a solid tumor impair perfusion and promotes therapy resistance is essential for treatment of disease.

The ImPRESS project is based on the following observations; (I) pre-clinical work suggests that therapies targeting the tumor microenvironment and extracellular matrix may enhance drug delivery by decompressing tumor vessels; (II) results from animal models may not be transferable because compressive forces in human tumors in vivo can be many times higher; and (III) there are no available imaging technologies for medical diagnostics of solid stress in human cancers. Using RPI, ImPRESS will conduct a comprehensive series of innovative studies in brain cancer patients to answer three key questions: (Q1) Can we image vascular restrictions in human cancers and map how the vasculature changes with tumor growth or treatment? (Q2) Can we use medical engineering to image solid stress in vivo? (Q3) Can RPI show that matrix-depleting drugs improve patient response to conventional chemo- and radiation therapy as well as new targeted therapies?

The ImPRESS project holds a unique position to answer these questions by our unrivaled experience with advanced imaging of cancer patients. With successful delivery, ImPRESS will have a direct impact on patient treatment and establish an imaging paradigm that will pave the way for new scientific knowledge on how to revitalize cancer therapies.

Publications

List of publications.
year	authors and title	journal	last update
2018	Stelios Angeli, Kyrre E. Emblem, Paulina Due-Tonnessen, Triantafyllos Stylianopoulos Towards patient-specific modeling of brain tumor growth and formation of secondary nodes guided by DTI-MRI published pages: 664-673, ISSN: 2213-1582, DOI: 10.1016/j.nicl.2018.08.032	NeuroImage: Clinical 20	2020-01-21
2018	Ingrid Digernes, Endre GrÃ¸vik, Line B. Nilsen, Cathrine Saxhaug, Oliver Geier, Edmund Reitan, Dag Ottar SÃ¦tre, Birger Breivik, Timothy Reese, Kari Dolven Jacobsen, Ã…slaug Helland, Kyrre Eeg Emblem Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery published pages: 559-567, ISSN: 2452-1094, DOI: 10.1016/j.adro.2018.05.005	Advances in Radiation Oncology 3/4	2020-01-21

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMPRESS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMPRESS" are provided by the European Opendata Portal: CORDIS opendata.